Filtered By:
Specialty: Urology & Nephrology
Condition: Heart Attack
Therapy: Dialysis

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 77 results found since Jan 2013.

Mechanisms of Stroke in Patients with Chronic Kidney Disease.
Abstract BACKGROUND: Given the increasing worldwide prevalence of chronic kidney disease (CKD), it is critical to decrease the associated risk of debilitating vascular complications, including stroke, congestive heart failure, myocardial infarction, and peripheral vascular disease. Treatment options for reducing the risk of all subtypes of stroke in patients with CKD remain limited. For patients with end-stage kidney disease (ESKD), novel applications of noninvasive imaging may help personalize the type of dialysis and dialysis prescription for patients at high-risk. SUMMARY: This manuscript reviews the heigh...
Source: American Journal of Nephrology - August 27, 2019 Category: Urology & Nephrology Authors: Ghoshal S, Freedman BI Tags: Am J Nephrol Source Type: research

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type  2 Diabetic Patients With CKD
Conclusions Most ESRD cases occurred in individuals without intercurrent CV events who had lower eGFRs than individuals with intercurrent CV events, but similar post-ESRD mortality. Nevertheless, intercurrent CV events, particularly heart failure, are strongly associated with risk for ESRD. These findings underscore the need for kidney-specific therapies in addition to treatment of CV risk factors to lower ESRD incidence in diabetes.
Source: American Journal of Kidney Diseases - June 7, 2017 Category: Urology & Nephrology Source Type: research

Valvular calcification upon initiating dialysis predict the appearance of cardiovascular events in patient evolution.
CONCLUSIONS: The prevalence of VC at the commencement of dialysis is very high and its presence is an independent predictor of event and cardiovascular mortality presentation in the course of follow-up. PMID: 26300509 [PubMed - as supplied by publisher]
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - August 25, 2015 Category: Urology & Nephrology Tags: Nefrologia Source Type: research

Renal physiology and kidney stones
Conclusions: The occurrence of a kidney stone is associated with an increased risk of cardiovascular events including AMI, death due to CHD,PTCA/CABG and stroke. These data suggest that people with a clinically recognized kidney stone should be followed more closely to evaluate for the possibility of subsequent cardiovascular events -- younger people and women.
Source: Nephrology Dialysis Transplantation - May 10, 2013 Category: Urology & Nephrology Authors: Alexander, R. T., Samuel, S., Wiebe, N., Bello, A., Klarenbach, S., Curhan, G. C., Tonelli, M., Hemmelgarn, B., Mingione, A., Terranegra, A., Aloia, A., Arcidiacono, T., Brasacchio, C., Hou, J., Dell'Antonio, G., Vezzoli, G., Soldati, L., Shimizu, T., Has Tags: Abstracts Source Type: research

Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.
CONCLUSIONS: In patients with kidney failure and nonvalvular atrial fibrillation, treatment with apixaban was not associated with a lower incidence of new stroke, transient ischemic attack, or systemic thromboembolism but was associated with a higher incidence of fatal or intracranial bleeding. PMID: 32444398 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - May 21, 2020 Category: Urology & Nephrology Authors: Mavrakanas TA, Garlo K, Charytan DM Tags: Clin J Am Soc Nephrol Source Type: research

Low Plasma α-Tocopherol Concentrations and Adverse Clinical Outcomes in Diabetic Hemodialysis Patients.
CONCLUSIONS: Plasma α-tocopherol concentrations were not independently associated with cardiovascular outcomes, infectious deaths, or all-cause mortality in diabetic hemodialysis patients. The lack of association can partly be explained by a confounding influence of malnutrition, which should be considered in the planning of trials to reduce cardiovascular risk in dialysis patients. PMID: 23335039 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - January 18, 2013 Category: Urology & Nephrology Authors: Espe KM, Raila J, Henze A, Blouin K, Schneider A, Schmiedeke D, Krane V, Pilz S, Schweigert FJ, Hocher B, Wanner C, Drechsler C, for the German Diabetes and Dialysis Study Investigators Tags: Clin J Am Soc Nephrol Source Type: research

Use and safety of heparin-free maintenance hemodialysis in the USA
Conclusions Patient markers of increased risk of bleeding and facility region associated with heparin-free HD use. Despite the potential benefits of avoiding heparin use, heparin-free HD was not significantly associated with decreased hazards of death, bleeding or thrombosis, suggesting that it may be no safer than HD with heparin.
Source: Nephrology Dialysis Transplantation - June 18, 2013 Category: Urology & Nephrology Authors: Shen, J. I., Mitani, A. A., Chang, T. I., Winkelmayer, W. C. Tags: Intra- and Extracorporeal Treatment of Kidney Failure Source Type: research

Kidney Stones and Cardiovascular Events: A Cohort Study.
CONCLUSIONS: The occurrence of a kidney stone is associated with a higher risk of cardiovascular events, including AMI, PTCA/CABG, and stroke. PMID: 24311706 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - December 5, 2013 Category: Urology & Nephrology Authors: Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Samuel S, Klarenbach SW, Curhan GC, Tonelli M, for the Alberta Kidney Disease Network Tags: Clin J Am Soc Nephrol Source Type: research

Associations between GSTM1*0 and GSTA1*A genotypes with the risk of cardiovascular death among hemodialyses patients
Conclusions: Combined GSTM1*0/GSTA1*A genotype might be considered as genetic markers for cardiovascular death risk in ESRD patients, which may permit targeting of preventive and early intervention.
Source: BMC Nephrology - January 14, 2014 Category: Urology & Nephrology Authors: Sonja SuvakovTatjana DamjanovicTatjana PekmezovicJovana JakovljevicAna Savic-RadojevicMarija Pljesa-ErcegovacSlavica RadovanovicDragan SimicSteva PljesaMilos ZarkovicJasmina Mimic-OkaNada DimkovicTatjana Simic Source Type: research

Silent Cerebral Microbleeds and Longitudinal Risk of Renal and Cardiovascular Events in Patients with CKD.
CONCLUSIONS: In patients with CKD, the presence of microbleeds is a novel and independent predictor of both renal and cardiovascular disease end points. PMID: 27354659 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - June 26, 2016 Category: Urology & Nephrology Authors: Shima H, Mori T, Ooi M, Sonoda M, Shoji T, Ishimura E, Okamura M, Ishizaka N, Inaba M Tags: Clin J Am Soc Nephrol Source Type: research

Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform
Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia in patients with CKD, including those receiving dialysis, although clinical trials have identified risks associated with ESA use. We evaluated the effects of changes in dialysis payment policies and product labeling instituted in 2011 on mortality and major cardiovascular events across the United States dialysis population in an open cohort study of patients on dialysis from January 1, 2005, through December 31, 2012, with Medicare as primary payer. We compared observed rates of death and major cardiovascular events in 2011 and 2012 with expected ra...
Source: Journal of the American Society of Nephrology : JASN - September 29, 2016 Category: Urology & Nephrology Authors: Chertow, G. M., Liu, J., Monda, K. L., Gilbertson, D. T., Brookhart, M. A., Beaubrun, A. C., Winkelmayer, W. C., Pollock, A., Herzog, C. A., Ashfaq, A., Sturmer, T., Rothman, K. J., Bradbury, B. D., Collins, A. J. Tags: Clinical Epidemiology Source Type: research

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
ConclusionsDespite initiating dialysis therapy with a higher hemoglobin level, prior treatment with darbepoetin was not associated with a reduction in mortality, myocardial infarction, or heart failure in the first 180 days, but a higher frequency of stroke was observed. In the absence of more definitive data, this may inform decisions regarding the use of erythropoiesis-stimulating agents to treat mild to moderate anemia in patients with type 2 diabetes and chronic kidney disease nearing dialysis therapy initiation.
Source: American Journal of Kidney Diseases - December 19, 2018 Category: Urology & Nephrology Source Type: research

Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis
CONCLUSIONS: The Medicare reimbursement policy and Food and Drug Administration-recommended erythropoietin-stimulating agent dosing changes were associated with lower erythropoietin-stimulating agent use and lower hemoglobin levels. These changes in anemia care were associated with lower risks of major adverse cardiovascular event, stroke, mortality, and heart failure but higher risk of acute myocardial infarction among adults receiving hemodialysis.PMID:35589388 | DOI:10.2215/CJN.14361121
Source: Clinical Journal of the American Society of Nephrology : CJASN - May 19, 2022 Category: Urology & Nephrology Authors: Haesuk Park Raj Desai Xinyue Liu Steven M Smith Juan Hincapie-Castillo Linda Henry Amie Goodin Saraswathi Gopal Carl J Pepine Raj Mohandas Source Type: research

Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial
Conclusions Two 750-mg infusions of FCM are a safe and effective alternative to multiple lower dose iron sucrose infusions in NDD-CKD patients with iron-deficiency anemia.
Source: Nephrology Dialysis Transplantation - March 27, 2014 Category: Urology & Nephrology Authors: Onken, J. E., Bregman, D. B., Harrington, R. A., Morris, D., Buerkert, J., Hamerski, D., Iftikhar, H., Mangoo-Karim, R., Martin, E. R., Martinez, C. O., Newman, G. E., Qunibi, W. Y., Ross, D. L., Singh, B., Smith, M. T., Butcher, A., Koch, T. A., Goodnoug Tags: Chronic Kidney Disease Source Type: research